[Clinical experiences with the radiosensitizer Misonidazol (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003907:Dexamethasone / Q000494:pharmacology; D004347:Drug Interactions; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010672:Phenytoin / Q000494:pharmacology
D009593:Nitroimidazoles; D010672:Phenytoin; D003907:Dexamethasone; D008920:Misonidazole
Klinische Erfahrungen mit dem Strahlensensibilisator Misonidazol.